Publication of the Survival estimates in European cystic fibrosis patients by the RCMG researchers’ joint study
European Respiratory Journal (Impact Factor 16.67) published a paper by N. Kashirskaya from the FSBI RCMG Genetic Epidemiology Laboratory (headed by Prof. R. A. Zinchenko, Dr. of med. sci.), together with members of the Working Group on the Cystic Fibrosis Patient Registry of the European Cystic Fibrosis Society Board (ECFS).
This is the first study in Europe to have quantified the relationship between national socioeconomic factors and survival, and it found that countries with the lowest health care spending rates had nearly twice the risk ratio for death compared to countries with higher health care spending rates. Despite uniform European standards for CF treatment and a national health insurance system in almost all European countries, access to care and medications varies widely across Europe, especially in Eastern Europe. A more detailed understanding of how these differences in socioeconomic factors lead to poorer survival is critical to improving outcomes for CF patients from European countries with lower health care costs.
McKone EF, Ariti C, Jackson A, et al. Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study. Eur Respir J 2021; 58: 2002288 [DOI: 10.1183/13993003.02288-2020]